Xvivo
XVIVO Perfusion AB is a Swedish medical technology company that develops and sells proprietary machine perfusion devices, preservation solutions, and software for lung, heart, liver, and kidney transplantation, serving transplant centers, OPOs, and hospitals globally with a direct enterprise sales force and recurring consumables revenue.
- Company typePublic
- Founded1998
- HeadquartersGöteborg, Sweden
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Xvivo does
XVIVO Perfusion AB is a Swedish medical technology company founded in 1998 and listed on Nasdaq Stockholm, focused on extending the viability of transplanted organs through proprietary machine perfusion technology and preservation solutions. Its product portfolio spans all four major transplanted organs — lung, heart, liver, and kidney — covering approximately 98% of the transplant market, and includes capital equipment (XPS EVLP platform, Kidney Assist Transport, Kidney Assist, Liver Assist, Heart Assist Transport in pipeline), proprietary single-use consumables and solutions (PERFADEX Plus, STEEN Solution, disposable lung kits), and software platforms (XVIVO Insights for remote perfusion monitoring, XVIVO FlowHawk for organ offer management integrating with 85+ EHRs).
The company operates a device-plus-consumables revenue model: hospitals and transplant centers purchase perfusion capital equipment and generate recurring revenue through proprietary solutions and disposable kits, complemented by US-based organ recovery services (seven regional hubs, 2,500+ organs recovered) and Italy-based perfusion services. Distribution combines a direct enterprise sales force in core markets (Sweden, US, Netherlands, Italy, UK) with regional distributors across 25+ countries, and pricing is enterprise quote-based through multi-year contracts to clinical and OPO buyers. The competitive position rests on a 25-year evidence base (100+ peer-reviewed publications for Liver Assist alone), regulatory approvals across multiple jurisdictions, patented preservation solutions, and clinical training infrastructure (XVIVO Academy).
Xvivo firmographics
Firmographics- Name
- Xvivo
- Legal name
- XVIVO Perfusion AB
- Website
- https://xvivogroup.com
- Company type
- Public
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- XVIVO Perfusion AB is a Swedish medical technology company that develops and sells proprietary machine perfusion devices, preservation solutions, and software for lung, heart, liver, and kidney transplantation, serving transplant centers, OPOs, and hospitals globally with a direct enterprise sales force and recurring consumables revenue.
- Ownership category
- akta.pro rank
Xvivo industry classification
Industry- Product category
- Organ Perfusion and Preservation Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Infusion Pumps (Ambulatory/Stationary) (HLAHAIAF)
Keywords
Where Xvivo is headquartered
LocationHeadquarters
- HQ city
- Göteborg
- HQ country
- Sweden
- HQ region
- Europe
Offices5 records
Markets served
Xvivo business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Medical Device Hardware Sales: XVIVO generates revenue primarily through the sale of perfusion devices (XPS, Kidney Assist Transport, Liver Assist, XVIVO Heart Assist Transport) and associated disposable products (XPS Disposable Lung Kit, STEEN Solution, PERFADEX Plus). The company manufactures and sells proprietary organ preservation equipment to transplant centers globally.
- Organ Recovery Services: XVIVO provides organ recovery services in the US market through dedicated teams of thoracic surgeons and surgical assistants available 24/7. The service recovers donor organs and coordinates transportation to transplant clinics through logistics partners. Operating from seven hubs on the East Coast and Midwest.
- Perfusion Services: XVIVO offers perfusion services where qualified perfusionists join transplant teams to oversee the entire perfusion process. Currently available in Italy.
- XVIVO Academy Training: Training and education services including theoretical and practical machine perfusion training sessions, customized on-site training, and hands-on training at the Groningen facility. Also includes webinars and masterclasses with key opinion leaders.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise/B2B quote-based pricing |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
Xvivo product offering
Product offeringCore offering
XVIVO develops, manufactures, and sells medical devices and proprietary solutions for machine perfusion and preservation of lungs, kidneys, livers, and hearts prior to transplantation. Its portfolio spans capital perfusion systems (XPS, Kidney Assist, Kidney Assist Transport, Liver Assist, Heart Assist Transport), single-use perfusates (PERFADEX Plus, STEEN Solution), disposable procedure kits, the XVIVO Insights remote-monitoring app, and the XVIVO FlowHawk organ offer management platform, complemented by organ recovery and perfusion services.
Product overview
XVIVO offers a comprehensive organ perfusion and preservation portfolio spanning four major organs (lung, heart, liver, kidney), addressing approximately 98% of the transplant market. The core product line includes machine perfusion devices (XPS for lung EVLP, Kidney Assist Transport, Kidney Assist, Liver Assist, and Heart Assist Transport in pipeline) and preservation solutions (PERFADEX Plus for static cold storage of lungs, STEEN Solution for EVLP). These devices are complemented by disposable accessories (Lung Cannula Set, Organ Chamber, XPS Disposable Lung Kit) and integrated software platforms (XVIVO Insights for remote perfusion monitoring, XVIVO FlowHawk for organ intake workflow management). Services include the U.S.-based Organ Recovery Service with seven regional hubs and the Italy-based Perfusion Service, supported by XVIVO Academy training programs. The company also supports Investigator Initiated Research (IIR) programs. The architecture follows a device-plus-consumables model where hospitals purchase/perfusion devices and recurring revenue comes from proprietary solutions (STEEN Solution, PERFADEX Plus) and disposable kits.
Differentiator
Problem solved
Functional benefit
Brands
- XVIVO Insights: Remote monitoring solution mobile app for tracking perfusion runs
- XVIVO FlowHawk
- XVIVO Organ Recovery Service
- XVIVO Perfusion Service
- XVIVO Academy
Products and services
- XPS (XVIVO Perfusion System) Comprehensive EVLP (Ex Vivo Lung Perfusion) platform providing an integrated overview of the entire normothermic lung perfusion process with all required components for running EVLP procedures using STEEN Solution. Used by transplant programs performing lung assessment.
- PERFADEX Plus Ready-to-use extracellular preservation solution for flushing, cold static storage, and transportation of isolated lungs. Proprietary, patented formulation pre-buffered with THAM and pre-supplemented with calcium ions, used as the gold-standard solution by over 90% of lung transplant clinics globally.
- Kidney Assist Transport Portable device enabling hypothermic pulsatile perfusion of donor kidneys with oxygenated solution (HOPE) for up to 24 hours, designed for easy set-up in unsterile transport settings.
- Kidney Assist Hospital-based device for pressure-controlled, oxygenated ex-vivo perfusion of donor kidneys with flexible temperature range (12–37°C) and integrated sensors.
- Liver Assist Device for liver machine perfusion supporting multiple protocols including HOPE, DHOPE, normothermic, sub-normothermic, or combinations. Backed by 100+ peer-reviewed publications and five randomized control trials.
- STEEN Solution Buffered extracellular solution used as physiological priming fluid and perfusate in ex-vivo lung perfusion procedures. The most frequently used solution for normothermic EVLP since the first clinical procedure in 2000.
- XVIVO Heart Assist Transport Device for hypothermic oxygenated perfusion (HOPE) of donor hearts, currently in clinical investigation through the PRESERVE Trial for non-ischemic heart preservation from extended donors.
- XVIVO Insights HIPAA-compliant remote monitoring platform and free mobile app for tracking perfusion runs on Kidney Assist Transport and Liver Assist devices, featuring GPS tracking, push notifications, and data export.
- XVIVO FlowHawk HIPAA-compliant communication and collaboration platform streamlining organ offer management, transplant center intake, post-transplant care, and living donor management, with integrations into 85+ EHR systems.
- XVIVO Organ Recovery Service Full-service organ recovery service in the U.S. with dedicated thoracic surgeons and surgical assistants available 24/7, operating from seven regional hubs and recovering over 2,500 organs to date.
- XVIVO Perfusion Service Service providing qualified perfusionists who join transplant teams to oversee the entire perfusion process, currently available in Italy.
- XVIVO Academy Educational platform providing webinars, masterclasses, scientific summaries, on-demand learning, and customized hands-on machine perfusion training at the Groningen facility or partner sites worldwide.
Quantifiable outcome
- 92.1% primary effectiveness endpoint success rate at day 30 in PRESERVE Trial
- +13 more outcomes
Companies that use Xvivo
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Xvivo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration14 records
Feature10 records
Xvivo partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered core and minor.
- Indiana Donor NetworkcoreIndiana Donor Network partnered with XVIVO and Perfusion Solution to deploy the first in-house machine perfusion system for marginal lungs in the U.S. On January 29, 2026, donated lungs initially rejected by several regional transplant centers were reassessed and successfully transplanted. This partnership established Indiana Donor Network as the first U.S. organ recovery organization with in-house lung perfusion capability.
- Perfusion Solution Inc. (PSI)coreWisconsin-based Perfusion Solution partnered with XVIVO and Indiana Donor Network to implement lung perfusion technology. PSI delivers the TA-NRP (Thoracoabdominal Normothermic Regional Perfusion) solution as part of XVIVO's organ recovery service, providing experienced surgeons, certified perfusionist staffing, operational support, and logistics expertise.
- ColigomedicalminorDistributor covering South Africa market with product portfolio including Abdominal and Thoracic products.
- AMI Technologies LTDminorDistributor covering Israel market.
- Vatska Medtech Private LimitedminorDistributor covering India market with Thoracic product portfolio.
- Stark Medical Pty LtdminorDistributor covering Australia and New Zealand market with Abdominal product portfolio.
- Pharmapal (Overseas) LtdminorDistributor covering Saudi Arabia and UAE (MENA region).
- Velamed Tıbbi ÜrünlerminorDistributor covering Turkey market.
- Biomotek Internacional SA DE CVminorDistributor covering Mexico market.
- Mespharma S.A.S.minorDistributor covering Colombia market.
- Almedis SpAminorDistributor covering Chile market.
- Pro-Gem d.o.o.minorDistributor covering Croatia and Slovenia markets.
- Reg-Pharm s.r.o.minorDistributor covering Czech Republic and Slovakia markets.
- InfusionminorDistributor covering Poland market.
- Pro Medical Baltic UAB ProminorDistributor covering Estonia, Lithuania, Latvia, and Kazakhstan markets.
- LLC MiamedminorDistributor covering Ukraine market.
- Pharma Hosting Peru SACminorDistributor covering Peru market.
Scale indicators13 records
Recent moves9 records
Expansion highlights6 records
Xvivo competitors and assessment
Company assessmentDirect peers
- TransMedics Group: TransMedics (Nasdaq: TMDX) develops the Organ Care System (OCS) for heart, lung, and liver preservation with normothermic perfusion. Most direct competitor to XVIVO across multiple organ platforms, particularly in the U.S. heart preservation market where PRESERVE trial results will compete against OCS Heart.
- OrganOx: OrganOx commercializes the metra normothermic liver perfusion device, a direct competitor to XVIVO's Liver Assist. Both companies target the same liver transplant centers with machine perfusion solutions, and OrganOx has established presence in European and U.S. markets.
- Paragonix Technologies: Paragonix develops hypothermic preservation and transport devices for donor hearts (SherpaPak) and other organs. They compete directly with XVIVO in the heart preservation space, particularly with XVIVO's Heart Assist Transport pipeline product targeting the same extended-criteria donor heart market.
- Institut Georges Lopez (IGL): IGL is a major manufacturer of preservation solutions including Perfadex and competes with XVIVO's PERFADEX Plus and STEEN Solution. They also acquired Waters Medical Systems, expanding into hypothermic perfusion devices that compete with Kidney Assist Transport.
- Dr. Franz Köhler Chemie: German pharmaceutical company producing cardioplegia and organ preservation solutions including Custodiol HTK. They are a competing supplier of preservation solutions to transplant centers, directly overlapping with XVIVO's solution portfolio.
- Bridge to Life: Bridge to Life supplies preservation solutions (Belzer MPS, IGL formulations) and is a direct competitor to XVIVO's PERFADEX Plus in the lung and abdominal organ preservation solution market. They serve many of the same transplant centers globally.
Emerging players
- Somahlution: Somahlution develops DuraGraft and other vascular/preservation solutions, including organ preservation research. They are an emerging player in the broader transplant preservation space with some technology overlap with XVIVO's solution portfolio.
- Traferox Technologies: Traferox develops preservation and transportation devices for organs and tissues, with focus on emerging perfusion technologies. They represent an emerging competitor in niche organ preservation segments where XVIVO operates.
Others
- Eurofins Scientific: Eurofins provides clinical diagnostics and laboratory testing services including transplant-related HLA typing and post-transplant monitoring. They are an adjacent player serving transplant centers, comparable to XVIVO's customer base, though not a direct technology competitor.
- QIAGEN: QIAGEN provides molecular diagnostics and sample preparation technologies used in transplant-related infectious disease screening and HLA typing. They serve the same transplant center customers as XVIVO with complementary diagnostics offerings, not direct competition in organ preservation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Xvivo social profiles
Digital presenceXvivo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Xvivo leadership team
Management profileNumber of profiles
Profiles6 records
Xvivo subsidiaries and ownership
Company hierarchySubsidiaries3 records
Xvivo funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Xvivo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Xvivo
What does Xvivo do?
XVIVO develops, manufactures, and sells medical devices and proprietary solutions for machine perfusion and preservation of lungs, kidneys, livers, and hearts prior to transplantation. Its portfolio spans capital perfusion systems (XPS, Kidney Assist, Kidney Assist Transport, Liver Assist, Heart Assist Transport), single-use perfusates (PERFADEX Plus, STEEN Solution), disposable procedure kits, the XVIVO Insights remote-monitoring app, and the XVIVO FlowHawk organ offer management platform, complemented by organ recovery and perfusion services.
Is Xvivo a public or private company?
Xvivo is a public company. It is classified as public and is currently operating.
When was Xvivo founded?
Xvivo was founded in 1998. It employs 101 to 250 people.
Where is Xvivo based?
Xvivo is headquartered in Göteborg, Sweden, in the Europe region.
How does Xvivo make money?
Four revenue lines are on record. Medical Device Hardware Sales are the primary driver. The others are organ Recovery Services, perfusion Services and XVIVO Academy Training.
Who are Xvivo's main competitors?
Direct peers on record are TransMedics Group, OrganOx, Paragonix Technologies, Institut Georges Lopez (IGL), Dr. Franz Köhler Chemie and Bridge to Life. Emerging players are Somahlution and Traferox Technologies. Others are Eurofins Scientific and QIAGEN.
Does Xvivo have an API?
No public API is recorded for Xvivo.
What industry is Xvivo in?
Xvivo's product category is Organ Perfusion and Preservation Medical Devices. Its primary akta.pro industry code is HLAHAIAF, Infusion Pumps (Ambulatory/Stationary). Its NAICS code is 339113 and its SIC code is 3841.